2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994




    

Company Abstracts  ::  2001

2001 Presentation Abstracts   2001 Publications Abstracts


EFFECT OF LJP 394 OR HIGH DOSE CORTICOSTEROIDS AND CYCLOPHOSPHAMIDE ON ANTI-dsDNA ANTIBODIES IN SLE PATIENTS
MD Linnik, et al.
Presented at
The 65th Annual Scientific Meeting of the American College of Rheumatology
San Francisco, California
Nov. 11-15, 2001



THE B-CELL TOLERAGEN LJP-394 REDUCES RENAL FLARES IN PATIENTS WITH LUPUS NEPHRITIS: A PROSPECTIVE DOUBLE-BLINDED, PLACEBO CONTROLLED TRIAL

J.A. Tumlin, M. D., et al.
Presented at
The ASN / ISN World Congress of Nephrology 2001
San Francisco, California
Oct. 10-17, 2001



USE OF MUTATIONS IN DOMAIN 1 AND DOMAIN 4 OF ß2GPI TO DETERMINE FINE ANTIGENIC SPECIFICITY OF ANTIPHOSPHOLIPID AUTOANTIBODIES
G. Michael Iverson, et al.
Presented at
The 27th Annual Conference of the La Jolla Immunologists
La Jolla, California
Oct. 23 & 24, 2001

Also presented at
The 18th Congress of the International Society on Thrombosis and Haemostasis
Paris, France
Jul. 6-12, 2001




DIVERGENT GROWTH OF BRANCHED CARBAMATES: INTERMEDIATES FOR CONSTRUCTING MULTIVALENT PLATFORMS
David S. Jones, et al.
Presented at
The 221st ACS National Meeting
San Diego, California
Apr. 1-5, 200



SYNTHESIS OF A TETRAVALENT CONJUGATE OF THE FIRST DOMAIN OF b2GPI: SITE SPECIFIC ATTACHMENT OF A PROTEIN TO A MULTIVALENT PLATFORM

David S. Jones, et al.
Presented at
The 221st ACS National Meeting
San Diego, California
Apr. 1-5, 2001


SLE TRIAL SHOWS FEWER RENAL FLARES IN LJP 394-TREATED PATIENTS WITH HIGH-AFFINITY ANTIBODIES TO LJP 394: 90-05 TRIAL RESULTS

D Alarcon-Segovia, et al.
Presented at
The 6th International Lupus Conference
Barcelona, Spain
Mar. 24-28, 2001



EFFECT OF LJP 394 ON SLE PATIENTS WITH IMPAIRED RENAL FUNCTION
Matthew D Linnik, et al.
Presented at
The 6th International Lupus Conference
Barcelona, Spain
Mar. 24-28, 2001



AFFINITY OF ANTIBODIES FOR LJP 394 INFLUENCES PHARMACODYNAMIC RESPONSE TO LJP 394 IN SLE PATIENTS
Matthew D. Linnik, et al.
Presented at
The 6th International Lupus Conference
Barcelona, Spain
Mar. 24-28, 2001


A NOVEL THERAPEUTIC APPROACH FOR TREATING ANTIPHOSPHOLIPID SYNDROME BASED ON TOLERIZING ANTI-ß2-GPI B CELLS
Matthew D. Linnik, et al.
Presented at the 26th International Stroke Conference
Fort Lauderdale, Florida
Feb. 14-16, 2001



SYNTHESIS OF MULTIVALENT CARBONATE ESTERS BY DIVERGENT GROWTH OF BRANCHED CARBAMATES
DS Jones, et al.
Published in
Tetrahedron Letters
2001 42: 2069-2072


CLINICAL AND PHARMACOLOGICAL EXPERIENCE WITH LJP-394
Wallace DJ
Published in
Expert Opinion on Investigational Drugs
2001 Volume 10: pp. 111-117


BIOSTABILITY AND PHARMACOKINETICS OF LJP 920, AN OCTAMERIC GAL (a1-3) GAL CONJUGATE FOR THE INHIBITION OF XENOTRANSPLANTATION REJECTION
Lee Jia, et al.
Published in Journal of Pharmacy and Pharmacology
53 (2001) 999-1005.


IDENTIFICATION OF A PEPTIDE THAT PROTECTS THE HUMAN ACETYLCHOLINE RECEPTOR AGAINST ANTIGENIC MODULATION
Luo GX, et al.
Published in the Journal of Immunological Methods, 2001;251: 177-186



PRE-TREATMENT AFFINITY FOR LJP 394 INFLUENCES PHARMACODYNAMIC RESPONSE IN LUPUS PATIENTS
McNeeley PA, et al.
Published in Lupus, 2001;10: 526-532



BETA 2-GLYCOPROTEIN I-DEPENDENT ANTICARDIOLIPIN ANTIBODIES PREFERENTIALLY BIND THE AMINO TERMINAL DOMAIN OF BETA 2-GLYCOPROTEIN 1
McNeeley PA, et al.
Published in Thrombosis and Haemostasis, 2001;86: 590-595

SYNTHESIS OF LJP 993, A MULTIVALENT CONJUGATE OF THE N-TERMINAL DOMAIN OF B2GPI AND SUPPRESSION OF AND ANTI- B2GPI IMMUNE RESPONSE
Jones DS, et al.
Published in Bioconjugate Chemistry,
2001;12:1012-1020.


TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS WITH LJP394
Richard A. Furie,
Published in the
Journal of Rheumatology,
2001; 28: 257-265


 

 


 






Terms of Use & Privacy Policy
Copyright © 2007, La Jolla Pharmaceutical Company